Modulators of Mas-related G-protein receptor X4 and related products and methods
Adam Yeager, San Diego, CA (US); Brandon Selfridge, San Diego, CA (US); Marcos Sainz, San Diego, CA (US); Esther Martinborough, San Diego, CA (US); Marcus Boehm, San Diego, CA (US); and Liming Huang, San Diego, CA (US)
Assigned to Escient Pharmaceuticals, Inc., San Diego, CA (US)
Filed by Escient Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Jul. 6, 2022, as Appl. No. 17/858,840.
Application 17/531,662 is a division of application No. 16/831,638, filed on Mar. 26, 2020, abandoned.
Application 17/858,840 is a continuation of application No. 17/531,662, filed on Nov. 19, 2021, abandoned.
Claims priority of provisional application 62/959,799, filed on Jan. 10, 2020.
Claims priority of provisional application 62/955,967, filed on Dec. 31, 2019.
Claims priority of provisional application 62/938,277, filed on Nov. 20, 2019.
Claims priority of provisional application 62/864,306, filed on Jun. 20, 2019.
Claims priority of provisional application 62/849,095, filed on May 16, 2019.
Claims priority of provisional application 62/825,741, filed on Mar. 28, 2019.
Prior Publication US 2023/0159474 A1, May 25, 2023
1. A method for modulating a Mas-Related G-Protein Receptor (MRGPR) X4 by contacting the MRGPRX4 with an effective amount of a compound having one of the following structures, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: